Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T‐cell therapy.

Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy Key sentences CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy is an innovative treatment[1] for patients with diffuse large B-cell lymphoma (DLBCL). Keywords: chimeric antigen receptor T cell (CAR-T); cytokine release syndrome (CRS); hypophosphataemia; predictive marker EN chimeric antigen receptor T cell (CAR-T) cytokine release syndrome (CRS) hypophosphataemia predictive marker e1 e3 3 12/22/22 20230101 NES 230101 Decreased serum iP can be a predictive marker for subsequent severe CRS. [Extracted from the article]